Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CD138 Monoclonal Antibody (359103), APC
Rat Monoclonal Antibody
Supplier: Invitrogen™ MA523540
Description
In direct ELISAs, this antibody shows approximately 60% cross-reactivity with recombinant mouse (rm) Syndecan-1 and no cross-reactivity with recombinant human (rh) Syndecan-2, rhSyndecan-3, or rmSyndecan-4.
CD138 (syndecan 1) is a transmembrane proteoglycan that can bind a variety of cytokines and modulate their activity, as well as the activity of extracellular matrix components and influence many developmental processes. CD138 is expressed mainly in differentiating keratinocytes and is transiently upregulated in all layers of the epidermis upon tissue injury. It is also highly expressed on plasma cells and can be detected even on fibroblasts, vascular smooth muscle cells and endothelial cells. Up-regulation and down-regulation of CD138 on the cell surface often correlates with the gain of cancerous characteristics. Serum levels of the shedded soluble sCD138 are used as a prognostic factor of cancerogenesis.
Specifications
CD138 | |
Monoclonal | |
APC | |
Sdc1 | |
AA408134; AA409076; CD antigen 138; CD138; CD138 antigen; heparan sulfate proteoglycan fibroblast growth factor receptor; HSPG; sCD138; SDC; Sdc1; soluble CD138; Sstn; syn-1; Synd; SYND1; Synd-1; SYNDECA; syndecan; syndecan 1; syndecan proteoglycan 1; Syndecan1; syndecan-1; synstatin | |
Rat | |
Protein A/G | |
RUO | |
6382 | |
4°C, store in dark, DO NOT FREEZE! | |
Liquid |
Flow Cytometry | |
359103 | |
Buffered saline solution with BSA and 0.09% sodium azide | |
P18827 | |
Sdc1 | |
Mouse myeloma cell line NS0-derived recombinant human Syndecan-1/CD138 Gln18-Glu251. | |
100 Tests | |
Primary | |
Human | |
Antibody | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction